Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Polikapran (Polycapran) is an absorbable local hemostatic agent developed by the Research Institute for Physical Chemical Problems of the Belarusian State University. It is composed of monocarboxycellulose (oxidized cellulose), a biodegradable polymer that facilitates the arrest of capillary and parenchymal bleeding. Upon contact with blood, Polikapran reacts with hemoglobin to form a gelatinous mass that serves as a matrix for fibrin clot formation and adheres to the wound surface. The material is biocompatible and undergoes complete enzymatic resorption within 14 to 30 days, eliminating the need for secondary surgical removal. It is primarily indicated for use in general surgery, dentistry, and trauma to manage bleeding from surgical sites and injuries.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on polikapran.